Small Molecule Inhibitors of the LEDGF Site of Human Immunodeficiency Virus Integrase Identified by Fragment Screening and Structure Based Design

被引:48
作者
Peat, Thomas S. [1 ]
Rhodes, David I. [2 ]
Vandegraaff, Nick [2 ]
Le, Giang [2 ]
Smith, Jessica A. [2 ]
Clark, Lisa J. [2 ]
Jones, Eric D. [2 ]
Coates, Jonathan A. V. [2 ]
Thienthong, Neeranat [2 ]
Newman, Janet [1 ]
Dolezal, Olan [1 ]
Mulder, Roger [3 ]
Ryan, John H. [3 ]
Savage, G. Paul [3 ]
Francis, Craig L. [3 ]
Deadman, John J. [2 ]
机构
[1] CSIRO Mat Sci & Engn, Parkville, Vic, Australia
[2] Avexa Ltd, Melbourne, Vic, Australia
[3] CSIRO Mat Sci & Engn, Clayton, Vic, Australia
来源
PLOS ONE | 2012年 / 7卷 / 07期
关键词
HIV-1; INTEGRASE; CATALYTIC DOMAIN; BINDING DOMAIN; RALTEGRAVIR; MECHANISM; PROTEIN; MODEL; CORE;
D O I
10.1371/journal.pone.0040147
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A fragment-based screen against human immunodeficiency virus type 1 (HIV) integrase led to a number of compounds that bound to the lens epithelium derived growth factor (LEDGF) binding site of the integrase catalytic core domain. We determined the crystallographic structures of complexes of the HIV integrase catalytic core domain for 10 of these compounds and quantitated the binding by surface plasmon resonance. We demonstrate that the compounds inhibit the interaction of LEDGF with HIV integrase in a proximity AlphaScreen assay, an assay for the LEDGF enhancement of HIV integrase strand transfer and in a cell based assay. The compounds identified represent a potential framework for the development of a new series of HIV integrase inhibitors that do not bind to the catalytic site of the enzyme.
引用
收藏
页数:11
相关论文
共 49 条
[1]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[2]   Early Emergence of Raltegravir Resistance Mutations in Patients Receiving HAART Salvage Regimens [J].
Baldanti, Fausto ;
Paolucci, Stefania ;
Gulminetti, Roberto ;
Brandolini, Micaela ;
Barbarini, Giorgio ;
Maserati, Renato .
JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (01) :116-122
[3]   Rare LEDGF/p75 genetic variants in white long-term nonprogressor HIV plus individuals [J].
Ballana, Ester ;
Gonzalo, Encarna ;
Grau, Eulalia ;
Iribarren, Jose A. ;
Clotet, Bonaventura ;
Este, Jose A. .
AIDS, 2012, 26 (04) :527-528
[4]  
Ceccherini-Silberstein F, 2009, AIDS REV, V11, P17
[5]   CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from α-defensin-1 HIV inhibition [J].
Chang, TLY ;
François, F ;
Mosoian, A ;
Klotman, ME .
JOURNAL OF VIROLOGY, 2003, 77 (12) :6777-6784
[6]   Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding [J].
Chen, JCH ;
Krucinski, J ;
Miercke, LJW ;
Finer-Moore, JS ;
Tang, AH ;
Leavitt, AD ;
Stroud, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) :8233-8238
[7]   Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 [J].
Cherepanov, P ;
Ambrosio, ALB ;
Rahman, S ;
Ellenberger, T ;
Engelman, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (48) :17308-17313
[8]   Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75 [J].
Cherepanov, P ;
Sun, ZYJ ;
Rahman, S ;
Maertens, G ;
Wagner, G ;
Engelman, A .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2005, 12 (06) :526-532
[9]   Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase [J].
Cherepanov, P ;
Devroe, E ;
Silver, PA ;
Engelman, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48883-48892
[10]   HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells [J].
Cherepanov, P ;
Maertens, G ;
Proost, P ;
Devreese, B ;
Van Beeumen, J ;
Engelborghs, Y ;
De Clercq, E ;
Debyser, Z .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (01) :372-381